Invivyd secures $30M loan facility to develop COVID-19 monoclonal antibody, avoiding share dilution.

From GlobeNewswire: 2025-04-21 07:01:00

Invivyd, Inc. (Nasdaq: IVVD) secured a $30 million term loan facility with Silicon Valley Bank (SVB) to support the development of its monoclonal antibody candidate, VYD2311, for COVID-19. The financing enables Invivyd to focus on value creation without diluting shares. VYD2311 is designed to offer clinically meaningful titer levels through intramuscular administration to address the urgent need for new therapeutic options for COVID-19. The company’s investigational mAb, PEMGARDA, has demonstrated neutralizing activity against major SARS-CoV-2 variants and is authorized for emergency use for pre-exposure prophylaxis in certain immunocompromised individuals. Visit Invivyd’s website for more information.



Read more at GlobeNewswire: Invivyd Announces $30M Non-dilutive Loan Facility with